|
|
HLA and lung transplantation |
Liya Ju1(), Caroline Suberbielle2, Xiaofan Li3, Nuala Mooney3,4, Dominique Charron1,2,4,5 |
1. HLA et Medecine, “Jean Dausset” Laboratory Network, Hôpital Saint-Louis, Paris, France 2. Laboratoire Histocompatibilité, Hôpital Saint-Louis, Paris, France 3. INSERM U1160, Hôpital Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité, France 4. Labex Transplantex, Strasbourg, France 5. Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China |
|
|
Abstract Lung transplantation is increasingly practiced for patients with end-stage lung disease. The successful outcome of solid organ transplantation today is severely impeded by the production of alloantibodies, mainly directed against the protein products of the HLA complex of the organ donor. While the association between antibody mediated rejection and allograft damage has been well established in renal and heart transplantation, it has not yet been well characterized in lung transplantation. This review addresses the question of HLA matching in lung transplantation and current knowledge of the allogenicity of different HLA class I and II antigens. The role of the antibody mediated immune response is discussed as well as the importance of pre-transplant or de novo post-transplant circulating antibodies. Finally, potential mechanisms, which may act individually or in combination, of antibody mediated damage to solid organ transplants are considered.
|
Keywords
human leukocyte antigen class I and II
lung transplantation
mismatch
obliterans bronchiolitis
alloantibody
antibody mediated rejection
|
Corresponding Author(s):
Liya Ju
|
Just Accepted Date: 10 May 2018
Online First Date: 05 July 2018
Issue Date: 05 June 2019
|
|
1 |
RD Yusen, LB Edwards, AY Kucheryavaya, C Benden, AI Dipchand, F Dobbels, SB Goldfarb, BJ Levvey, LH Lund, B Meiser, J; International Society for Heart and Lung Transplantation Stehlik. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report—2014; focus theme: retransplantation. J Heart Lung Transplant 2014; 33(10): 1009–1024
https://doi.org/10.1016/j.healun.2014.08.004
pmid: 25242125
|
2 |
Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients(SRTR). OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, 2011
|
3 |
DJ Levine, AR Glanville, C Aboyoun, J Belperio, C Benden, GJ Berry, R Hachem, D Hayes Jr, D Neil, NL Reinsmoen, LD Snyder, S Sweet, D Tyan, G Verleden, G Westall, RD Yusen, M Zamora, A Zeevi. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2016; 35(4): 397–406
https://doi.org/10.1016/j.healun.2016.01.1223
pmid: 27044531
|
4 |
W McManigle, EN Pavlisko, T Martinu. Acute cellular and antibody-mediated allograft rejection. Semin Respir Crit Care Med 2013; 34(3): 320–335
https://doi.org/10.1055/s-0033-1348471
pmid: 23821507
|
5 |
C Auffray, D Charron, L Hood. Predictive, preventive, personalized and participatory medicine: back to the future. Genome Med 2010; 2(8): 57
https://doi.org/10.1186/gm178
pmid: 20804580
|
6 |
J Robinson, JA Halliwell, JH Hayhurst, P Flicek, P Parham, SGE Marsh. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res 2015;43(Database issue):D423–431 doi: 10.1093/nar/gku1161
|
7 |
W Wisser, T Wekerle, G Zlabinger, O Senbaclavaci, A Zuckermann, W Klepetko, E Wolner. Influence of human leukocyte antigen matching on long-term outcome after lung transplantation. J Heart Lung Transplant 1996; 15(12): 1209–1216
pmid: 8981206
|
8 |
JMA Smits, BJA Mertens, HC Van Houwelingen, A Haverich, GG Persijn, G Laufer. Predictors of lung transplant survival in eurotransplant. Am J Transplant 2003; 3(11): 1400–1406
https://doi.org/10.1046/j.1600-6143.2003.00231.X
pmid: 14525601
|
9 |
MA Quantz, LE Bennett, DM Meyer, RJ Novick. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,549 lung transplantations. J Heart Lung Transplant 2000; 19(5): 473–479
https://doi.org/10.1016/S1053-2498(00)00081-4
pmid: 10808155
|
10 |
JY Wong, B Tait, B Levvey, A Griffiths, DS Esmore, GI Snell, TJ Williams, TC Kotsimbos. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease. Transplantation 2004; 78(2): 205–210
https://doi.org/10.1097/01.TP.0000128611.71038.0C
pmid: 15280679
|
11 |
NA Bakker , GW van Imhoff, EA Verschuuren, WJ van Son, JJ van der Heide, SP Lems , NJ Veeger, PM Kluin , HC Kluin-Nelemans, BG Hepkema . HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation 2005; 80(5):595–599
pmid: 16177631
|
12 |
G Opelz, C Süsal, A Ruhenstroth, B Döhler. Impact of HLA compatibility on lung transplant survival and evidence for an HLA restriction phenomenon: a collaborative transplant study report. Transplantation 2010; 90(8): 912–917
https://doi.org/10.1097/TP.0b013e3181f2c981
pmid: 20808265
|
13 |
D Jr Hayes, BA Whitson, SN Ghadiali, JD Tobias, HM Mansour, SM Black. Influence of HLA mismatching on survival in lung transplantation. Lung 2015; 193(5): 789–797
https://doi.org/10.1007/s00408-015-9768-9
pmid: 26220289
|
14 |
D Jr Hayes, SM Black, JD Tobias, BT Kopp, SE Kirkby, HM Mansour, BA Whitson. Influence of human leukocyte antigen mismatching on bronchiolitis obliterans syndrome in lung transplantation. J Heart Lung Transplant. 2016; 35(2):186–194
https://doi.org/10.1016/j.healun.2015.08.022
|
15 |
AL Harjula, JC Baldwin, AR Glanville, H Tazelaar, PE Oyer, EB Stinson, NE Shumway. Human leukocyte antigen compatibility in heart-lung transplantation. J Heart Transplant 1987; 6(3): 162–166
pmid: 3116183
|
16 |
S Sundaresan, T Mohanakumar, MA Smith, EP Trulock, J Lynch, D Phelan, JD Cooper, GA Patterson. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998; 65(5): 648–653
https://doi.org/10.1097/00007890-199803150-00008
pmid: 9521198
|
17 |
O Brugière, G Thabut, C Suberbielle, M Reynaud-Gaubert, P Thomas, C Pison, C Saint Raymond, JF Mornex, M Bertocchi, C Dromer, JF Velly, M Stern, B Philippe, G Dauriat, G Biondi, Y Castier, M Fournier. Relative impact of human leukocyte antigen mismatching and graft ischemic time after lung transplantation. J Heart Lung Transplant 2008; 27(6): 628–634
https://doi.org/10.1016/j.healun.2008.02.013
pmid: 18503962
|
18 |
M Peltz, L Bennett Edwards, ME Jessen, F Torres, DM Meyer. Impact of HLA class I and class II mismatching on lung transplant recipient mortality, rejection, and bronchiolitis obliterans. J Heart Lung Transplant 2006; 25(suppl): S112
https://doi.org/10.1016/j.healun.2005.11.205
|
19 |
W Chalermskulrat, IP Neuringer, JL Schmitz, DJ Catellier, MJ Gurka, SH Randell, RM Aris. Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest 2003; 123(6): 1825–1831
https://doi.org/10.1378/chest.123.6.1825
pmid: 12796156
|
20 |
LL Schulman, AD Weinberg, C McGregor, ME Galantowicz, NM Suciu-Foca, S Itescu. Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation. Am J Respir Crit Care Med 1998; 157(6 Pt 1): 1833–1837
https://doi.org/10.1164/ajrccm.157.6.9707007
pmid: 9620914
|
21 |
Y Iwaki, Y Yoshida, B Griffith. The HLA matching effect in lung transplantation. Transplantation 1993; 56(6): 1528–1564
https://doi.org/10.1097/00007890-199312000-00047
pmid: 8279029
|
22 |
RB Love, KC Meyer, LD Devito-Haynes, S Ulschmid, GE Leverson, W Van Der Bij, WJ De Boer, BG Hepkema, RD Cornwell, DS Woolley, WJ Burlingham. Effect of HLA-DR mismatch on lung transplant outcome. J Heart Lung Transplant 2001; 20(2): 177
https://doi.org/10.1016/S1053-2498(00)00356-9
pmid: 11250286
|
23 |
L Wan, DF Chen. The influence of HLA antigen mismatch and epitope mismathe on lung transplant survival: analysis of OPTN data after LAS allocation. Hum Immunol 2015; 76: 124–167
https://doi.org/10.1016/j.humimm.2015.07.174
|
24 |
RJ Butts, AJ Savage, PJ Nietert, M Kavarana, O Moussa, AL Burnette, AM Atz. Effect of human leukocyte antigen-C and-DQ matching on pediatric heart transplant graft survival. J Heart Lung Transplant 2014; 33(12): 1282–1287
https://doi.org/10.1016/j.healun.2014.07.014
pmid: 25128416
|
25 |
B Afzali, G Lombardi, RI Lechler. Pathways of major histocompatibility complex allorecognition. Curr Opin Organ Transplant 2008; 13(4): 438–444
https://doi.org/10.1097/MOT.0b013e328309ee31
pmid: 18685342
|
26 |
OB Herrera, D Golshayan, R Tibbott, F Salcido Ochoa, MJ James, FM Marelli-Berg, RI Lechler. A novel pathway of alloantigen presentation by dendritic cells. J Immunol 2004; 173(8): 4828–4837
https://doi.org/10.4049/jimmunol.173.8.4828
pmid: 15470023
|
27 |
RA Shilling, DS Wilkes. Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond. Am J Transplant 2009; 9(8): 1714–1718
https://doi.org/10.1111/j.1600-6143.2009.02690.x
pmid: 19519813
|
28 |
RR Hachem. Lung allograft rejection: diagnosis and management. CurrOpinOrgan Transplant 2009;14(5):477–482
https://doi.org/DOI: 10.1097/MOT.0b013e32832fb981
|
29 |
JS Pober, D Jane-wit, L Qin, G Tellides. Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy. Arterioscler Thromb Vasc Biol 2014; 34(8): 1609–1614
https://doi.org/10.1161/ATVBAHA.114.302818
pmid: 24903097
|
30 |
MM DeNicola, SS Weigt, JA Belperio, EF Reed, DJ Ross, WD Wallace. Pathologic findings in lung allografts with anti-HLA antibodies. J Heart Lung Transplant 2013; 32(3): 326–332
https://doi.org/10.1016/j.healun.2012.11.018
pmid: 23313559
|
31 |
J Visentin, A Chartier, L Massara, G Linares, G Guidicelli, E Blanchard, M Parrens, H Begueret, C Dromer, JL Taupin. Lung intragraft donor-specific antibodies as a risk factor for graft loss. J Heart Lung Transplant 2016; 35(12): 1418–1426
https://doi.org/10.1016/j.healun.2016.06.010
pmid: 27450460
|
32 |
R Hachem. Antibody-mediated lung transplant rejection. Curr Respir Care Rep 2012; 1(3): 157–161
https://doi.org/10.1007/s13665-012-0019-8
pmid: 23002428
|
33 |
2004 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994–2003. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI
|
34 |
CL Lau, SM Palmer, KE Posther, DN Howell, NL Reinsmoen, HT Massey, VF Tapson, JJ Jaggers, TA D’Amico, RD Davis Jr. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg 2000; 69(5): 1520–1524
https://doi.org/10.1016/S0003-4975(00)01224-8
pmid: 10881834
|
35 |
AS Shah, L Nwakanma, C Simpkins, J Williams, DC Chang, JV Conte. Pretransplant panel reactive antibodies in human lung transplantation: an analysis of over 10,000 patients. Ann Thorac Surg 2008; 85(6): 1919–1924
https://doi.org/10.1016/j.athoracsur.2008.02.011
pmid: 18498795
|
36 |
AA Mangi, DP Mason, ER Nowicki, LH Batizy, SC Murthy, DJ Pidwell, RK Avery, KR McCurry, GB Pettersson, EH Blackstone. Predictors of acute rejection after lung transplantation. Ann Thorac Surg 2011; 91(6): 1754–1762
https://doi.org/10.1016/j.athoracsur.2011.01.076
pmid: 21536252
|
37 |
TO Hirche, C Knoop, H Hebestreit. Practical guidelines: lung transplantation in patients with cystic fibrosis. Pulm Med 2014; 2014:621342
|
38 |
JK Choi, J Kearns, HI Palevsky, KT Montone, LR Kaiser, CM Zmijewski, JE Tomaszewski. Hyperacute rejection of a pulmonary allograft. Immediate clinical and pathologic findings. Am J Respir Crit Care Med 1999; 160(3): 1015–1018
https://doi.org/10.1164/ajrccm.160.3.9706115
pmid: 10471633
|
39 |
AE Frost, CT Jammal, PT Cagle. Hyperacute rejection following lung transplantation. Chest 1996; 110(2): 559–562
https://doi.org/10.1378/chest.110.2.559
pmid: 8697867
|
40 |
HB Bittner, J Dunitz, M Hertz, MR 3rd Bolman, SJ Park. Hyperacute rejection in single lung transplantation—case report of successful management by means of plasmapheresis and antithymocyte globulin treatment. Transplantation 2001; 71(5): 649–651
https://doi.org/10.1097/00007890-200103150-00012
pmid: 11292295
|
41 |
E Masson, M Stern, J Chabod, C Thévenin, F Gonin, JM Rebibou, P Tiberghien. Hyperacute rejection after lung transplantation caused by undetected low-titer anti-HLA antibodies. J Heart Lung Transplant 2007; 26(6): 642–645
https://doi.org/10.1016/j.healun.2007.03.007
pmid: 17543791
|
42 |
A Loupy, C Lefaucheur, D Vernerey, C Prugger, JP Duong van Huyen, N Mooney, C Suberbielle, V Frémeaux-Bacchi, A Méjean, F Desgrandchamps, D Anglicheau, D Nochy, D Charron, JP Empana, M Delahousse, C Legendre, D Glotz, GS Hill, A Zeevi, X Jouven. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369(13): 1215–1226
https://doi.org/10.1056/NEJMoa1302506
pmid: 24066742
|
43 |
A Sicard, S Ducreux, M Rabeyrin, L Couzi, B McGregor, L Badet, JY Scoazec, T Bachelet, S Lepreux, J Visentin, P Merville, V Fremeaux-Bacchi, E Morelon, JL Taupin, V Dubois, O Thaunat. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol 2015; 26(2): 457–467
https://doi.org/10.1681/ASN.2013101144
pmid: 25125383
|
44 |
AR Tambur, FH Claas. HLA epitopes as viewed by antibodies: what is it all about? Am J Transplant 2015; 15(5): 1148–1154
https://doi.org/10.1111/ajt.13192
pmid: 25708017
|
45 |
Q Zhang, JM Cecka, DW Gjertson, P Ge, ML Rose, JK Patel, A Ardehali, JA Kobashigawa, MC Fishbein, EF Reed. HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation 2011; 91(10): 1153–1158
https://doi.org/10.1097/TP.0b013e3182157d60
pmid: 21544036
|
46 |
RR Hachem, RD Yusen, BF Meyers, AA Aloush, T Mohanakumar, GA Patterson, EP Trulock. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 2010; 29(9): 973–980
https://doi.org/10.1016/j.healun.2010.05.006
pmid: 20558084
|
47 |
LJ Lobo, RM Aris, J Schmitz, IP Neuringer. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant 2013; 32(1): 70–77
https://doi.org/10.1016/j.healun.2012.10.007
pmid: 23260706
|
48 |
LD Snyder, Z Wang, DF Chen, NL Reinsmoen, CA Finlen-Copeland, WA Davis, DW Zaas, SM Palmer. Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest 2013; 144(1): 226–233
https://doi.org/10.1378/chest.12-0587
pmid: 23328795
|
49 |
AL Girnita, KR McCurry, AT Iacono, R Duquesnoy, TE Corcoran, M Awad, KJ Spichty, SA Yousem, G Burckart, JH Dauber, BP Griffith, A Zeevi. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 2004; 23(10): 1135–1141
https://doi.org/10.1016/j.healun.2003.08.030
pmid: 15477106
|
50 |
SM Palmer, RD Davis, D Hadjiliadis, MI Hertz, DN Howell, FE Ward, K Savik, NL Reinsmoen. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002; 74(6): 799–804
https://doi.org/10.1097/00007890-200209270-00011
pmid: 12364858
|
51 |
EP Trulock, JD Christie, LB Edwards, MM Boucek, P Aurora, DO Taylor, F Dobbels, AO Rahmel, BM Keck, MI Hertz. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report—2007. J Heart Lung Transplant 2007; 26(8): 782–795
https://doi.org/10.1016/j.healun.2007.06.003
pmid: 17692782
|
52 |
BD Tait, C Süsal, HM Gebel, PW Nickerson, AA Zachary, FH Claas, EF Reed, RA Bray, P Campbell, JR Chapman, PT Coates, RB Colvin, E Cozzi, II Doxiadis, SV Fuggle, J Gill, D Glotz, N Lachmann, T Mohanakumar, N Suciu-Foca, S Sumitran-Holgersson, K Tanabe, CJ Taylor, DB Tyan, A Webster, A Zeevi, G Opelz. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95(1): 19–47
https://doi.org/10.1097/TP.0b013e31827a19cc
pmid: 23238534
|
53 |
A Jaramillo, MA Smith, D Phelan, S Sundaresan, EP Trulock, JP Lynch, JD Cooper, GA Patterson, T Mohanakumar. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999; 67(8): 1155–1161
https://doi.org/10.1097/00007890-199904270-00012
pmid: 10232567
|
54 |
AL Girnita, R Duquesnoy. YousemSA, Iacono AT, Corcoran TE, Buzoianu M, Johnson B, Spichty KJ, Dauber JH, Burckart G, Griffith BP, McCurry KR, Zeevi A. HLA-specific antibodies are risk factors forlymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005; 5: 131–138
https://doi.org/10.1111/j.1600-6143.2004.00650.x
pmid: 15636621
|
55 |
F Cardarelli, M Pascual, N Tolkoff-Rubin, FL Delmonico, W Wong, DA Schoenfeld, H Zhang, AB Cosimi, SL Saidman. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int 2005; 18(5): 532–540
https://doi.org/10.1111/j.1432-2277.2005.00085.x
pmid: 15819801
|
56 |
N Lachmann, PI Terasaki, C Schönemann. Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up. Clin Transpl 2006; 2006:171–199
pmid: 18365377
|
57 |
HG Otten, MC Verhaar, HP Borst, RJ Hené, AD van Zuilen. Pretransplant donor-specific HLA class-I and-II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012; 12(6): 1618–1623
https://doi.org/10.1111/j.1600-6143.2011.03985.x
pmid: 22404993
|
58 |
SI Reznik, A Jaramillo, L Zhang, GA Patterson, JD Cooper, T Mohanakumar. Anti-HLA antibody binding to HLA class I molecules induces proliferation of airway epithelial cells: a potential mechanism for bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 2000; 119(1): 39–45
https://doi.org/10.1016/S0022-5223(00)70215-7
pmid: 10612759
|
59 |
M Kim, KR Townsend, IG Wood, S Boukedes, I Guleria, S Gabardi, S El-Chemaly, PC Camp, AK Chandraker, EL Milford, HJ Goldberg. Impact of pretransplant anti-HLA antibodies on outcomes in lung transplant candidates. Am J Respir Crit Care Med 2014; 189(10): 1234–1239
https://doi.org/10.1164/rccm.201312-2160OC
pmid: 24749479
|
60 |
C Wiebe, D Pochinco, TD Blydt-Hansen, J Ho, PE Birk, M Karpinski, A Goldberg, LJ Storsley, IW Gibson, DN Rush, PW Nickerson. Class II HLA epitope matching—a strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transpl 2013; 13: 3114–3122
|
61 |
RB Colvin. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18(4): 1046–1056
https://doi.org/10.1681/ASN.2007010073
pmid: 17360947
|
62 |
EY Song, YJ Lee, J Hyun, YS Kim, C Ahn, J Ha, SJ Kim, MH Park. Clinical relevance of pretransplant HLA class II donor-specific antibodies in renal transplantation patients with negative T-cell cytotoxicity crossmatches. Ann Lab Med 2012; 32(2): 139–144
https://doi.org/10.3343/alm.2012.32.2.139
pmid: 22389881
|
63 |
M Bieri, M Oroszlan, A Farkas, N Ligeti, J Bieri, P Mohacsi. Anti-HLA I antibodies induce VEGF production by endothelial cells, which increases proliferation and paracellular permeability. Int J Biochem Cell Biol 2009; 41(12): 2422–2430
https://doi.org/10.1016/j.biocel.2009.06.009
pmid: 19577661
|
64 |
C Lefaucheur, A Loupy, GS Hill, J Andrade, D Nochy, C Antoine, C Gautreau, D Charron, D Glotz, C Suberbielle-Boissel. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21(8): 1398–1406
https://doi.org/10.1681/ASN.2009101065
pmid: 20634297
|
65 |
C Lefaucheur, C Antoine, C Suberbielle, D Glotz. Mastering the risk of HLA antibodies in kidney transplantation: an algorithm based on pretransplant single-antigen flow bead techniques. Am J Transplant 2011; 11(8): 1592–1598
https://doi.org/10.1111/j.1600-6143.2011.03560.x
pmid: 21668626
|
66 |
S Safavi, DR Robinson, S Soresi, M Carby, JD Smith. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2014; 33(12): 1273–1281
https://doi.org/10.1016/j.healun.2014.07.012
pmid: 25130554
|
67 |
CA Witt, JP Gaut, RD Yusen, DE Byers, JA Iuppa, K Bennett Bain, G Alexander Patterson, T Mohanakumar, EP Trulock, RR Hachem. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant 2013; 32(10): 1034–1040
https://doi.org/10.1016/j.healun.2013.07.004
pmid: 23953920
|
68 |
JD Smith, NR Banner, IM Hamour, M Ozawa, A Goh, D Robinson, PI Terasaki, ML Rose. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11(2): 312–319
https://doi.org/10.1111/j.1600-6143.2010.03383.x
pmid: 21219570
|
69 |
A Roux, I Bendib Le Lan, S Holifanjaniaina, KA Thomas, AM Hamid, C Picard, D Grenet, S De Miranda, B Douvry, L Beaumont-Azuar, E Sage, J Devaquet, E Cuquemelle, M Le Guen, R Spreafico, C Suberbielle-Boissel, M Stern, F; Foch Lung Transplantation Group. ParquinAntibody-mediated rejection in lung transplantation: clinical outcomes and donor-specific antibody characteristics. Am J Transplant 2016; 16(4): 1216–1228
https://doi.org/10.1111/ajt.13589
pmid: 26845386
|
70 |
D Kopchaliiska, J Kukreja, G Dincheva, E Bush, L Leard, J Singer, M Brzezinski, S Hays, R Rajalingam. IVIG infusion deplete donor-specific HLA antibodies in lung transplant recipients: a single-center experience. Hum Immunol 2015; 76(Suppl): 14–37
|
71 |
M Stern, H Hirsch, A Cusini, C van Delden, O Manuel, P Meylan, K Boggian, NJ Mueller, M Dickenmann; Members of Swiss Transplant Cohort Study. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation 2014; 98(9): 1013–1018
https://doi.org/10.1097/TP.0000000000000160
pmid: 24837540
|
72 |
L Baxter-Lowe, J Singer, S Hays, J Kukreja, J Golden, L Leard .Late after lung transplantation many patients have donor-specific HLA antibodies (DSA) and high DSA levels appear to be associated with poor outcomes. Am J Transplant 2013; 13 (suppl 5) [abstract]
|
73 |
A Zeevi, M Marrari, K Spichty, M Morrell, C Gries, J McDyer, J Pilewski, D Zaldonis, J Bhama, N Shigemura, S Yousem, R Duquesnoy, J D’Cunha, C Bermudez. Increased frequency of class II HLA-DQ donor-specific antibodies is associated with mixed cellular and humoral rejection in lungtransplantation. J Heart Lung Transplant 2013; 32(4 4S): S76
https://doi.org/10.1016/j.healun.2013.01.190
|
74 |
JM Tikkanen, LG Singer, SJ Kim, Y Li, M Binnie, C Chaparro, CW Chow, T Martinu, S Azad, S Keshavjee, K Tinckam. De novo DQ donor-specific antibodies are associated with chronic lung allograft dysfunction after lung transplantation. Am J Respir Crit Care Med 2016; 194(5): 596–606
https://doi.org/10.1164/rccm.201509-1857OC
pmid: 26967790
|
75 |
A Loupy, C Lefaucheur, D Vernerey, C Prugger, JP Duong van Huyen, N Mooney, C Suberbielle, V Frémeaux-Bacchi, A Méjean, F Desgrandchamps, D Anglicheau, D Nochy, D Charron, JP Empana, M Delahousse, C Legendre, D Glotz, GS Hill, A Zeevi, X Jouven. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369(13): 1215–1226
https://doi.org/10.1056/NEJMoa1302506
pmid: 24066742
|
76 |
M Yell, BL Muth, DB Kaufman, A Djamali, TM Ellis. C1q binding activity of de novo donor-specific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection. Transplantation 2015; 99(6): 1151–1155
https://doi.org/10.1097/TP.0000000000000699
pmid: 25839705
|
77 |
A Sicard, S Ducreux, M Rabeyrin, L Couzi, B McGregor, L Badet, JY Scoazec, T Bachelet, S Lepreux, J Visentin, P Merville, V Fremeaux-Bacchi, E Morelon, JL Taupin, V Dubois, O Thaunat. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol 2015; 26(2): 457–467
https://doi.org/10.1681/ASN.2013101144
pmid: 25125383
|
78 |
MG Strainic, J Liu, D Huang, F An, PN Lalli, N Muqim, VS Shapiro, GR Dubyak, PS Heeger, ME Medof. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008; 28(3): 425–435
https://doi.org/10.1016/j.immuni.2008.02.001
pmid: 18328742
|
79 |
GP Westall, GI Snell, C McLean, T Kotsimbos, T Williams, C Magro. C3d and C4d deposition early after lung transplantation. J Heart Lung Transplant 2008; 27(7): 722–728
https://doi.org/10.1016/j.healun.2008.03.018
pmid: 18582800
|
80 |
EJ Lepin, Q Zhang, X Zhang, PT Jindra, LS Hong, P Ayele, MV Peralta, DW Gjertson, JA Kobashigawa, WD Wallace, MC Fishbein, EF Reed. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant 2006; 6(7): 1560–1571
https://doi.org/10.1111/j.1600-6143.2006.01355.x
pmid: 16827856
|
81 |
T Hirohashi, CM Chase, P Della Pelle, D Sebastian, A Alessandrini, JC Madsen, PS Russell, RB Colvin. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012; 12(2): 313–321
https://doi.org/10.1111/j.1600-6143.2011.03836.x
pmid: 22070565
|
82 |
X Zhang, EF Reed. Effect of antibodies on endothelium. Am J Transplant 2009; 9(11): 2459–2465
https://doi.org/10.1111/j.1600-6143.2009.02819.x
pmid: 19775314
|
83 |
F Li, J Wei, NM Valenzuela, C Lai, Q Zhang, D Gjertson, MC Fishbein, JA Kobashigawa, M Deng, EF Reed. Phosphorylated S6 kinase and S6 ribosomal protein are diagnostic markers of antibody-mediated rejection in heart allografts. J Heart Lung Transplant 2015; 34(4): 580–587
https://doi.org/10.1016/j.healun.2014.09.047
pmid: 25511749
|
84 |
S Le Bas-Bernardet, S Coupel, A Chauveau, JP Soulillou, B Charreau. Vascular endothelial cells evade apoptosis triggered by human leukocyte antigen-DR ligation mediated by allospecific antibodies. Transplantation 2004; 78(12): 1729–1739
https://doi.org/10.1097/01.TP.0000147339.31581.99
pmid: 15614145
|
85 |
J Lion, C Taflin, AR Cross, M Robledo-Sarmiento, E Mariotto, A Savenay, M Carmagnat, C Suberbielle, D Charron, A Haziot, D Glotz, N Mooney. HLA class II antibody activation of endothelial cells promotes Th17 and disrupts regulatory T lymphocyte expansion. Am J Transplant 2016; 16(5): 1408–1420
https://doi.org/10.1111/ajt.13644
pmid: 26614587
|
86 |
C Deteix, V Attuil-Audenis, A Duthey, N Patey, B McGregor, V Dubois, G Caligiuri, S Graff-Dubois, E Morelon, O Thaunat. Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J Immunol 2010; 184(9): 5344–5351
https://doi.org/10.4049/jimmunol.0902999
pmid: 20357253
|
87 |
HI Basha, S Ramachandran, V Tiriveedhi, M Takenaka, V Subramanian, DS Nath, N Benshoff, GA Patterson, T Mohanakumar. Critical role for IL-17A/F in the immunopathogenesis of obliterans airway disease induced by anti-MHC I antibodies. Transplantation 2013; 95(2): 293–300
https://doi.org/10.1097/TP.0b013e3182772244
pmid: 23325004
|
88 |
D Jane-wit, TD Manes, T Yi, L Qin, P Clark, NC Kirkiles-Smith, P Abrahimi, J Devalliere, G Moeckel, S Kulkarni, G Tellides, JS Pober. Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-kB signaling in endothelial cells. Circulation 2013; 128(23): 2504–2516 doi:10.1161/CIRCULATIONAHA.113.002972
pmid: 24045046
|
89 |
M Mezzetti, M Soloperto, A Fasoli, S Mattoli. Human bronchial epithelial cells modulate CD3 and mitogen-induced DNA synthesis in T cells but function poorly as antigen-presenting cells compared to pulmonary macrophages. J Allergy Clin Immunol 1991; 87(5): 930–938
https://doi.org/10.1016/0091-6749(91)90414-J
pmid: 1827479
|
90 |
AC Cunningham, JG Zhang, JV Moy, S Ali, JA Kirby. A comparison of the antigen-presenting capabilities of class II MHC-expressing human lung epithelial and endothelial cells. Immunology 1997; 91(3): 458–463
https://doi.org/10.1046/j.1365-2567.1997.d01-2249.x
pmid: 9301537
|
91 |
LG Hidalgo, J Sellares, B Sis, M Mengel, J Chang, PF Halloran. Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant 2012; 12(5): 1180–1191
https://doi.org/10.1111/j.1600-6143.2011.03970.x
pmid: 22390872
|
92 |
MD Parkes, PF Halloran, LG Hidalgo. Evidence for CD16a-mediated NK cell stimulation in antibody-mediated kidney transplant rejection. Transplantation 2017; 101(4): e102–e111
https://doi.org/10.1097/TP.0000000000001586
pmid: 27906829
|
93 |
D Saini, N Angaswamy, V Tiriveedhi, N Fukami, S Ramachandran, R Hachem, E Trulock, B Meyers, A Patterson, T Mohanakumar. Synergistic effect of antibodies to human leukocyte antigens and defensins in pathogenesis of bronchiolitis obliterans syndrome after human lung transplantation. J Heart Lung Transplant 2010; 29(12): 1330–1336
https://doi.org/10.1016/j.healun.2010.05.036
pmid: 20691611
|
94 |
N Fukami, S Ramachandran, D Saini, M Walter, W Chapman, GA Patterson, T Mohanakumar. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol 2009; 182(1): 309–318
https://doi.org/10.4049/jimmunol.182.1.309
pmid: 19109162
|
95 |
A Jaramillo, CR Smith, T Maruyama, L Zhang, GA Patterson, T Mohanakumar. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol 2003; 64(5): 521–529
https://doi.org/10.1016/S0198-8859(03)00038-7
pmid: 12691702
|
96 |
GS Hill, D Nochy, P Bruneval, JP Duong van Huyen, D Glotz, C Suberbielle, J Zuber, D Anglicheau, JP Empana, C Legendre, A Loupy. Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011; 22(5): 975–983
https://doi.org/10.1681/ASN.2010070777
pmid: 21493773
|
97 |
T Maruyama, A Jaramillo, K Narayanan, T Higuchi, T Mohanakumar. Induction of obliterans airway disease by anti-HLA class I antibodies. Am J Transplant 2005; 5(9): 2126–2134
https://doi.org/10.1111/j.1600-6143.2005.00999.x
pmid: 16095491
|
98 |
Y Yamada, Y Sekine, S Yoshida, K Yasufuku, I Petrache, HL Benson, DD Brand, I Yoshino, DS Wilkes. Type V collagen-induced oral tolerance plus low-dose cyclosporine prevents rejection of MHC class I and II incompatible lung allografts. J Immunol 2009; 183(1): 237–245
https://doi.org/10.4049/jimmunol.0804028
pmid: 19542435
|
99 |
Z Xu, DK Nayak, N Benshoff, R Hachem, AE Gelman, T Mohanakumar. De novo-developed antibodies to donor MHC antigens lead to dysregulation of microRNAs and induction of MHC class II. J Immunol 2015; 194(12): 6133–6143
https://doi.org/10.4049/jimmunol.1401848
pmid: 25941328
|
100 |
DK Nayak, F Zhou, M Xu, J Huang, M Tsuji, J Yu, R Hachem, AE Gelman, RM Bremner, MA Smith, T Mohanakumar. Zbtb7a induction in alveolar macrophages is implicated in anti-HLA-mediated lung allograft rejection. Sci Transl Med 2017; 9(398): eaal1243
https://doi.org/10.1126/scitranslmed.aal1243
pmid: 28701473
|
101 |
S Otani, AK Davis, L Cantwell, S Ivulich, A Pham, MA Paraskeva, GI Snell, GP Westall. Evolving experience of treating antibody-mediated rejection following lung transplantation. Transpl Immunol 2014; 31(2): 75–80
https://doi.org/10.1016/j.trim.2014.06.004
pmid: 25004453
|
102 |
GE Rodey, TC Fuller. Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol 1987; 7(3): 229–267
pmid: 2441930
|
103 |
MA Ayala García, B González Yebra, AL López Flores, E Guaní Guerra. The major histocompatibility complex in transplantation. J Transplant 2012; 2012: 842141
https://doi.org/10.1155/2012/842141
pmid: 22778908
|
104 |
G Opelz, J Mytilineos, S Scherer, H Dunckley, J Trejaut, J Chapman, D Middleton, D Savage, O Fischer, JD Bignon, JC Bensa, E Albert, H; Noreen The Collaborative Transplant Study. Survival of DNA HLA-DR typed and matched cadaver kidney transplants. Lancet 1991; 338(8765): 461–463
https://doi.org/10.1016/0140-6736(91)90540-6
pmid: 1678443
|
105 |
SK Takemoto, PI Terasaki, DW Gjertson, JM Cecka. Twelve years’ experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000; 343(15): 1078–1084
https://doi.org/10.1056/NEJM200010123431504
pmid: 11027742
|
106 |
P Rubinstein. HLA matching for bone marrow transplantation—how much is enough? N Engl J Med 2001; 345(25): 1842–1844
https://doi.org/10.1056/NEJM200112203452511
pmid: 11752363
|
107 |
T Kawase, K Matsuo, K Kashiwase, H Inoko, H Saji, S Ogawa, S Kato, T Sasazuki, Y Kodera, Y Morishima; Japan Marrow Donor Program.. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 2009; 113: 2851–2858
https://doi.org/10.1182/blood-2008-08-171934
pmid: 18997170
|
108 |
N Chin, M Paraskeva, E Paul, L Cantwell, B Levvey, T Williams, G Snell, G Westall. Comparative analysis of how immune sensitization is defined prior to lung transplantation. Hum Immunol 2015; 76(10): 711–716
https://doi.org/10.1016/j.humimm.2015.09.025
pmid: 26429328
|
109 |
CM Burton, M Iversen, N Milman, M Zemtsovski, J Carlsen, D Steinbrüchel, J Mortensen, CB Andersen. Outcome of lung transplanted patients with primary graft dysfunction. Eur J Cardiothorac Surg 2007; 31(1): 75–82
https://doi.org/10.1016/j.ejcts.2006.10.024
pmid: 17134909
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|